Verekitug
Product Specifications
CAS Number
2768386-15-6
Target
Immunology/Inflammation related, Interleukin
Related Pathways
Immunology/Inflammation
Purity
0.989
Bioactivity
Verekitug is a novel, recombinant, fully human monoclonal antibody developed to selectively target thymic stromal lymphopoietin receptor (TSLPR) with high potency. Verekitug is currently being investigated as a potential therapeutic candidate for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), where overactivation of TSLPR contributes to disease pathology. Verekitug offers a promising approach to immune modulation in respiratory and inflammatory disease research.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog